Wisner Baum Named to Leadership in Federal Spinal Cord Stimulator Litigation

Wisner Baum partner Behram V. Parekh was appointed one of three Co-Lead Counsels for the Boston Scientific spinal cord stimulator MDL (MDL No. 3181) in the Central District of California, as coordinated discovery ramps up. The MDL focuses on allegations of serious injuries (e.g., painful electrical shocks and neurologic symptoms) and on whether manufacturers made software/firmware and other device changes via FDA supplement pathways without sufficient new clinical trials. A separate consolidation push for Abbott and Nevro cases is scheduled for a Sept. 24 hearing, potentially expanding review across industry practices, but the article itself is procedural with no direct financial figures.

Analysis

This is a procedural step, not a fundamentals event. The market should read it as a lower-frequency but higher-conviction litigation setup: once leadership is in place, discovery becomes cheaper and faster, which raises the odds of bellwether sequencing, reserve-setting, and headline cadence over the next 3-9 months. For BSX, that argues for valuation multiple pressure rather than an immediate revenue hit; the real risk is a higher probability of material legal accruals or a settlement frame that forces the market to re-rate the device portfolio.

Second-order, the bigger issue is spillover into the broader neuromodulation category. If the JPML consolidates related Abbott and Nevro cases, the story shifts from a single-product dispute to a platform-level review of how device iterations were handled under the supplement pathway. That would not show up in revenue overnight, but it can change purchasing behavior at pain clinics and slow physician adoption for 1-3 quarters if the litigation narrative broadens to class-wide safety/process concerns.

Contrarian view: the move is likely overread in the very short term because leadership appointments mainly improve plaintiffs’ coordination, not liability. The bigger catalyst is the September hearing and then what discovery uncovers about design changes, adverse-event reporting, and FDA correspondence. If those records show ordinary post-approval modifications and no consistent adverse-event signal, the thesis fades; if they show cumulative changes without robust clinical support, this becomes a multi-quarter overhang with multiple compression for BSX and, to a lesser extent, ABT.

Key Decisions for Investors

• Short BSX on any relief rally into the Sep. 24 JPML hearing; use 4-8 week put spreads if implied vol is not already elevated. Risk/reward is better on a defined-risk structure because the near-term event is procedural, not binary.
• Pair trade: short BSX / long ABT over the next 1-3 months. BSX is more exposed to litigation multiple compression from a focused franchise, while ABT's diversification should cushion any reserve surprise. Falsifier: if Abbott is pulled into a broader coordinated MDL and BSX-specific cases stay narrow, cover the pair.
• Watchlist alert on Nevro-related names and the broader medtech ETF (IHI) rather than an outright short until consolidation is decided. A favorable JPML ruling for plaintiffs would raise category risk and could justify a basket hedge against neuromodulation exposure.
• No-action until discovery evidence: if early bellwether documents show FDA supplement changes were routine and adverse-event rates are not durable, cover BSX shorts. If discovery implies cumulative device modifications without new trials, add on weakness and target a 6-12 month hold.